GlassScriptPhysician profile
Leo J Spaccavento
NPI 1982793287
$9,652.27
in general payments reported to CMS, 2019-2025
34 companies · $1,008 in 2025
The $1,008 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $857 · 2020: $471 · 2021: $1,698 · 2022: $1,947 · 2023: $1,992 · 2024: $1,679 · 2025: $1,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,679.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,295.01 | 2019-2025 | Cardiomems, Gallant |
| Novartis Pharmaceuticals Corporation | $1,434.08 | 2019-2025 | |
| Medtronic, INC. | $568.40 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $544.90 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $518.09 | 2019-2025 | Camzyos, Eliquis |
| Cvrx, INC. | $463.96 | 2021-2025 | Barostim Neo System |
| Amgen INC. | $462.61 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $396.07 | 2022-2025 | Jardiance |
| Pfizer INC. | $294.05 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $290.32 | 2019-2023 | Opsumit, Uptravi |
| Sanofi-Aventis U.S. LLC | $277.46 | 2019-2024 | |
| Novo Nordisk INC | $264.03 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $234.39 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $188.99 | 2022-2025 | Verquvo |
| Boston Scientific Corporation | $173.43 | 2019-2025 | Watchman Flx |
Show all 34 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leo Spaccavento listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.